George DJ, Halabi S, Healy P, et al. - The combination of docetaxel prednisone with pazopanib, an oral vascular endothelial growth factor receptor inhibitor, was evaluated for safety and preliminary efficacy in men with metastatic castration-resistant prostate cancer. Researchers conducted a two-site phase 1b Department of Defense Prostate Cancer Clinical Trials Consortium trial of docetaxel, prednisone, and pazopanib once daily and ongoing androgen deprivation therapy and prophylactic pegfilgrastim in men with mCRPC. Treatment over six dose levels was received by 25 men. After myelosuppression limited dose escalation, an addition of pegfilgrastim to the regimen was done. With pegfilgrastim addition, they reached their target maximum tolerated dose of docetaxel 75 mg/m² q3 weeks; prednisone 10 mg daily; and pazopanib 800 mg daily. At this dose level, 11 additional patients were accrued for a total of 36 patients. Neutropenia, syncope, and hypertension were the dose-limiting toxicities. As per the findings, the patients well tolerated the combination of docetaxel, prednisone, and pazopanib (with pegfilgrastim) at full doses. Outcomes establishes the promising efficacy of this combination in relatively poor-risk patients with mCRPC.